REGENXBIO Inc.

NASDAQ:RGNX

Biotechnology

Healthcare
$7.26 +1.97%

+$0.16 today

Market cap
$480.05M
Beta
1.03
P/E (TTM)
-1.5
EPS (TTM)
-$5.53
52W Low $5.46High $16.19

Volume 0.70M

Average 1.24M

RGNX EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

REGENXBIO Inc.NASDAQ: RGNX

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA turns negative

Q1 FY2026 EBITDA was -$77.49M, compared with $18.61M a year earlier. Trailing-twelve-month EBITDA was -$229.35M.

Context

  • EBITDA amounted to 78.2% of revenue in FY2025, down 159.7 pp from a year earlier.
  • EBITDA grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 7 analysts of -$151.63M (-13.8%) for the fiscal year ending Dec 2026, a slowdown from the +32.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$77.49M-51.9% QoQ
Last fiscal yearDec 2025
-$133.26M+32.8% YoY
LTMMar 2026
-$229.35M-87.3% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-516.4%+132.3%+648.7 pp
1 year+32.8%-13.8%-46.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(133.26M) USD
Year-over-year change
+32.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How RGNX compares with its peers on the latest reported figures

  • RGNX's LTM Mar 2026 EBITDA of -$229.35M is the lowest of the 10 companies compared; the peer median is -$129.14M.
  • Its year-over-year change of -87.3% is the lowest of 10, against a peer median of +3.9%.
  • EBITDA amounts to 261.2% of revenue for RGNX, versus a peer median of 246.8%.
RGNX Competitors Peer median
EBITDA for RGNX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OCGNOcugen, Inc.LTM Mar 2026-$64.18M -19.1%—1437.5%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026-$85.19M +20.5%——
MGTXMeiraGTx Holdings plcLTM Mar 2026-$95.72M +32.5%—120.0%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-$112.54M -37.5%—308.4%
QUREuniQure N.V.LTM Mar 2026-$129.14M +6.4%—713.8%
PGENPrecigen, Inc.LTM Jun 2026-$143.84M -16.8%—167.8%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-$163.43M +3.9%—185.2%
SLDBSolid Biosciences Inc.LTM Mar 2026-$190.1M -38.9%——
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026-$194.47M +21.0%——
RGNXREGENXBIO Inc.LTM Mar 2026-$229.35M -87.3%—261.2%
Peer median (excluding RGNX) -$129.14M+3.9%—246.8%

Competitors are the stored peer set for RGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue470.35M112.72M90.24M83.33M170.44M
Cost of Revenue51.83M54.55M37.21M33.57M20.3M
Gross Profit418.51M58.18M53.03M49.76M150.14M
Gross Margin89.0%51.6%58.8%59.7%88.1%
Research & Development181.44M242.45M232.27M208.52M228.3M
Selling, General & Admin79.33M85.28M88.49M76.62M82.86M
Operating Expenses258.53M321.06M321.16M283.11M311.34M
Depreciation & Amortization9.56M12.91M17.32M16.22M15.62M
EBITDA177.09M(244.24M)(239.46M)(198.23M)(133.26M)
EBITDA Margin37.7%-216.7%-265.4%-237.9%-78.2%
Operating Income159.98M(262.88M)(268.13M)(233.35M)(161.2M)
Operating Margin34.0%-233.2%-297.1%-280.0%-94.6%
Interest Income719K342K25K174K12.27M
Interest Expense26.28M23.25M6.86M12.66M45.01M
Other Income / Expenses(18.73M)(17.53M)4.48M6.24M(32.68M)
Income Before Tax141.25M(280.41M)(263.65M)(227.1M)(193.88M)
Pre-Tax Margin30.0%-248.8%-292.2%-272.5%-113.8%
Income Tax Expense13.41M(84K)(152K)00
Net Income127.84M(280.32M)(263.49M)(227.1M)(193.88M)
Net Margin27.2%-248.7%-292.0%-272.5%-113.8%
EPS (Basic)3.01(6.50)(6.02)(4.59)(3.76)
EPS (Diluted)2.91(6.50)(6.02)(4.59)(3.76)
Weighted Avg Shares42.44M43.15M43.73M49.51M51.57M
Weighted Avg Shares (Diluted)43.91M43.15M43.73M49.51M51.57M

REGENXBIO Inc.

NASDAQ:RGNX

Intrinsic Alpha fair value

Locked

Current Price

$7.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.